Giant Biogene's (HKG:2367) attributable profit rose 42% to 2.06 billion yuan in 2024 from 1.45 billion yuan in 2023, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share at the skincare products maker increased 39% to 2.06 yuan from 1.48 yuan a year earlier. Analysts at Visible Alpha estimated EPS at 2.04 yuan.
Revenue grew 57% to 5.54 billion yuan from 3.52 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 5.26 billion yuan.
The company declared a final dividend of 0.6021 yuan per share and a special dividend of 0.5921 yuan per share, both payable Aug. 29 to shareholders on record as of June 24.
Shares rose 1% during Thursday's trading.